NSEAmendment to AOA/MOA10 Jul 2026 · 10 Jul 2026, 08:25 pm
Amendment to AOA/MOA
Orchid Pharma Limited · ORCHPHARMA
✦ AI SummaryM&A
Orchid Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, including the effectiveness of the Scheme, alteration of capital clause, fixing of record date, and share exchange ratio.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Attachments (1)
📄pdf
Download →
ORCHPHARMA_10072026202410_Stx_Ltr_Alter_MOA.pdf
View document text
Date: July 10, 2026
National Stock Exchange of India Limited, BSE Limited
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal
Bandra (E), Mumbai-400051 Street Fort, Mumbai- 400001
Symbol: ORCHPHARMA Scrip Code: 524372
Sub: Intimation under Regulations 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 as amended ("SEBI Listing Regulations").
Dear Sir/ Ma’am,
In terms of Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and in continuation of our
earlier intimation dated July 10, 2026, with respect to scheme becoming effective from July 10, 2026
and consequent dissolution of Dhanuka Laboratories Limited (“Amalgamating Company/DLL”) without
being Wound up, we wish to inform you that the Board of Directors of the Company, at its Meeting
held today i.e., July 10, 2026, concluded at 19:10 P.M. have, inter alia, considered, noted and
approved the following:
- Effectiveness of Scheme: Pursuant to completion of all the conditions as prescribed under
Clause 8 of the Scheme, the Scheme has been made effective today, i.e., July 10, 2026
(“Effective Date”) and Amalgamating Company stand dissolved without being wound up in
accordance with the terms of the Scheme.
- Appointed Date: The Appointed date as per the scheme is 1st April, 2024.
- Alteration of Capital Clause of Memorandum of Association: Pursuant to the effectiveness
of the Scheme, the authorized share capital has automatically stood increased on account of
transfer to and amalgamation of authorised capital of DLL with the authorized share capital of
Orchid Pharma Limited (“Amalgamated/OPL”). Accordingly, Clause V of the Memorandum of
Association (MoA) of OPL, has stood replaced by the following Clause V:
V. The Authorised Share Capital of the Company is Rs. 164,51,00,000 (rupees one hundred sixty
four crore and fifty one lakh only) divided into 16,45,10,000 (sixteen crore forty five lakh ten
thousand only) equity shares of Rs. 10/-(rupees ten only) each.
- Fixing of Record date: Pursuant to regulation 42 of SEBI Listing Regulations and in consultation
with the Amalgamating Company the record date for determining the shareholders of the
Amalgamating Company to whom the shares in Amalgamated Company would be issued under
the Scheme is Thursday, 23rd July, 2026.
- Share Exchange Ratio: Pursuant to Para 16 of Part III of Scheme share exchange ratio is as
follows:
"161 fully paid up equity shares of face value of INR 10/- (Indian Rupees Ten) of the Amalgamated
Company to be issued and allotted to the members of the Amalgamating Company against 5 fully
paid up equity share of face value of INR 100/- (Indian Rupees One Hundred) each held in the
Amalgamating Company."
You are requested to take the above intimation on record.
Thanking You
For Orchid Pharma Limited
Kapil Dayya
Company Secretary & Compliance Officer
Membership No.:F10698
Orchid Pharma Limited Regd. Office: Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist-603110, Tamil Nadu, India
Phone: (91)-44- 2744 4471/72/73 Email: Corporate@orchidpharma.com Website: www.orchidpharma.com CIN: L24222TN1992PLC022994